Clearmind Medicine Inc.

About Clearmind Medicine Inc.

Clearmind Medicine develops breakthrough psychedelic treatments for addiction and mental health issues, including alcohol use disorder, binge eating, and depression, aiming to address some of society's most complex and costly health challenges.

Products & Services

MEAI (5-Methoxy-2-aminoindane):A new psychoactive molecule that provides a euphoric alcohol-like experience and reduces the desire to consume alcoholic beverages, with potential to help millions drink in moderation.

Proprietary Treatment Candidates:A portfolio of treatments targeting addiction and mental health disorders, specifics not detailed in the content.

Specialties

Psychedelic Treatments Addiction Treatment Mental Health Alcohol Use Disorder Binge Behavior Depression

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Convertible Debt T: - FT: Convertible Debt	A: 10000000 MR: - FA: $10,000,000 FAN: 10000000	D: 2025-09-19 FD: 2025-09-19	1 investors
2	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 7000000 MR: - FA: $7.0 Million FAN: 7000000	D: 2024-01-24 FD: 2024-01-24	1 investors
3	RT: Registered Direct and Private Placement T: - FT: Registered Direct and Private Placement	A: 2400000 MR: - FA: $2.4 Million FAN: 2400000	D: 2024-01-16 FD: 2024-01-16	1 investors
4	RT: Private Placement T: - FT: Private Placement	A: 2400000 MR: - FA: 2.4 million FAN: 2400000	D: 2024-01-16 FD: 2024-01-16	1 investors
5	RT: Registered Direct and Private Placement T: - FT: Registered Direct and Private Placement	A: 2400000 MR: - FA: approximately $2.4 million FAN: 2400000	D: 2024-01-11 FD: 2024-01-11	1 investors
6	RT: Public Offering T: - FT: Public Offering	A: 3500000 MR: - FA: $3.5 Million FAN: 3500000	D: 2023-04-10 FD: 2023-04-10	-
7	RT: Public Offering T: - FT: Public Offering	A: 3500000 MR: - FA: US$3.5 million FAN: 3500000	D: 2023-04-06 FD: 2023-04-06	1 investors
8	RT: Public Offering T: - FT: Public Offering	A: 3500000 MR: - FA: US$3.5 Million FAN: 3500000	D: 2023-04-04 FD: 2023-04-04	1 investors

Convertible Debt Latest

2025-09-19

$10.0M

1 investor (Pro only)

Underwritten Public Offering 2024-01-24

$7.0M

Registered Direct and Private Placement 2024-01-16

$2.4M

View 7 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Adi Zuloff-Shani

CEO

A

Alan Rootenberg

Chief Financial Officer

M

Mark Haden

VP Business Development

G

Gadi Levin

VP Finance

S

Sara Horn

Clinical and Regulatory Affairs

A

Amit Shwartz

R&D Consultant

View 22 more team members with Pro

Unlock Full Team Directory

Recent News